Corporate Brochure - Daiichi Sankyo...Corporate Brochure H04-01 Corporate Philosophy Joji Nakayama...

Latest information

www.daiichisankyo.com

Corporate Brochure

■H04-01

Corporate Philosophy

Joji NakayamaRepresentative Director,

President and CEO

Dai ichi Sankyo’s mission is to contr ibute to t he

enrichment of the qual ity of l i fe around the world

through the creation of innovative pharmaceuticals

and through the provision of pharmaceuticals that

address diverse medical needs.

The business environment facing the pharmaceutical

industry continues to evolve in Japan and around

the world. In the midst of these changing conditions,

we are working to realize our vision of becoming a

Global Pharma Innovator. To that end, we are striving

to satisfy unmet medical needs as a developer of new

drugs, including vaccines, generic and OTC drugs, that

meet a variety of medical needs.

As a leader in the healthcare industry, we recognize

that we have multiple responsibili t ies to our many

stakeholders. We not only have a responsibilit y to

provide the pharmaceuticals that are indispensable

today to healthcare systems around the world, but we

must also fund the research and development that

ensures the availabil i ty of tomorrow’s innovative

medicines. We also have a responsibility to support the

communities in which we live and work. We commit to

achieving these important goals while delivering earnings

growth to our shareholders and doing our utmost to earn

the trust of all our stakeholders. By embracing these

responsibilities, we hope to be a company worthy of

representing Japan as a cutting-edge global enterprise.

Thank you for your continued support.

G loba l ad va nces i n me d ic a l t e chno lo g y and

pharmaceuticals have saved the lives of a great many

people and contributed to healthier lifestyles. However,

there are stil l many diseases for which the level of

satisfaction with treatment is insufficient or for which

there is no establ i shed t reatment . Preventat i ve

measures, treatments and therapies that can be

tailored to each patient’s particular condition are also in

great demand. Pharmaceutical companies play an

integral part in medical treatment and are depended

upon to p rov ide so lu t i ons to these p rob lems .

Daiichi Sankyo’s commitment to providing what people

really need is summed up in our corporate mission: “ To

contribute to the enrichment of quality of life around the

world through the creation of innovative pharmaceuticals,

and through the provision of pharmaceuticals addressing

diverse medical needs.” In order to fulfill this mission, the

Daiichi Sankyo Group has devoted itself with a strong

sense of duty to doing all that it can to meet society’s

expectations.

Message from the CEO

Based on our mission, we act with three values in mind—

namely, “innovation,” “integrity,” and “accountability”—

to pursue the following eight areas of commitment.

Our Values and Commitments

1. To create first-in-class and best-in-class drugs

2. To take a global perspective, and respect local values

3. To foster intellectual curiosity and strategic insight

Innovation “Our Imperative”

4. To provide the highest quality medical information

5. To provide a stable supply of top-quality

pharmaceutical products

6. To be an ethical, trusted, and respectful partner

7. To be accountable for achieving our goals

8. To demonstrate professionalism, respect for others

and teamwork

Accountability “Our Culture”

Integrity “Our Strength”

Latest information Latest information

At Daiichi Sankyo, our vision is to become a Global Pharma

Innovator that can meet diverse medical needs around the

world—a company that is capable of sustainable growth. In

keeping with this vision, we have proactively implemented a

range of initiatives, focusing on expanding the Group’s global

business reach, fulfilling unmet medical needs and building

innovative products and business models.

Vision

essageBusiness Strategy

Marketing

CSRHistory

Regional Activities

■Ｐ01-02

Corporate Philosophy

Joji NakayamaRepresentative Director,

President and CEO

Dai ichi Sankyo’s mission is to contr ibute to t he

enrichment of the qual ity of l i fe around the world

through the creation of innovative pharmaceuticals

and through the provision of pharmaceuticals that

address diverse medical needs.

The business environment facing the pharmaceutical

industry continues to evolve in Japan and around

the world. In the midst of these changing conditions,

we are working to realize our vision of becoming a

Global Pharma Innovator. To that end, we are striving

to satisfy unmet medical needs as a developer of new

drugs, including vaccines, generic and OTC drugs, that

meet a variety of medical needs.

As a leader in the healthcare industry, we recognize

that we have multiple responsibili t ies to our many

stakeholders. We not only have a responsibilit y to

provide the pharmaceuticals that are indispensable

today to healthcare systems around the world, but we

must also fund the research and development that

ensures the availabil i ty of tomorrow’s innovative

medicines. We also have a responsibility to support the

communities in which we live and work. We commit to

achieving these important goals while delivering earnings

growth to our shareholders and doing our utmost to earn

the trust of all our stakeholders. By embracing these

responsibilities, we hope to be a company worthy of

representing Japan as a cutting-edge global enterprise.

Thank you for your continued support.

G loba l ad va nces i n me d ic a l t e chno lo g y and

pharmaceuticals have saved the lives of a great many

people and contributed to healthier lifestyles. However,

there are stil l many diseases for which the level of

satisfaction with treatment is insufficient or for which

there is no establ i shed t reatment . Preventat i ve

measures, treatments and therapies that can be

tailored to each patient’s particular condition are also in

great demand. Pharmaceutical companies play an

integral part in medical treatment and are depended

upon to p rov ide so lu t i ons to these p rob lems .

Daiichi Sankyo’s commitment to providing what people

really need is summed up in our corporate mission: “ To

contribute to the enrichment of quality of life around the

world through the creation of innovative pharmaceuticals,

and through the provision of pharmaceuticals addressing

diverse medical needs.” In order to fulfill this mission, the

Daiichi Sankyo Group has devoted itself with a strong

sense of duty to doing all that it can to meet society’s

expectations.

Message from the CEO

Based on our mission, we act with three values in mind—

namely, “innovation,” “integrity,” and “accountability”—

to pursue the following eight areas of commitment.

Our Values and Commitments

1. To create first-in-class and best-in-class drugs

2. To take a global perspective, and respect local values

3. To foster intellectual curiosity and strategic insight

Innovation “Our Imperative”

4. To provide the highest quality medical information

5. To provide a stable supply of top-quality

pharmaceutical products

6. To be an ethical, trusted, and respectful partner

7. To be accountable for achieving our goals

8. To demonstrate professionalism, respect for others

and teamwork

Accountability “Our Culture”

Integrity “Our Strength”

At Daiichi Sankyo, our vision is to become a Global Pharma

Innovator that can meet diverse medical needs around the

world—a company that is capable of sustainable growth. In

keeping with this vision, we have proactively implemented a

range of initiatives, focusing on expanding the Group’s global

business reach, fulfilling unmet medical needs and building

innovative products and business models.

Vision

Marketing

CSRHistory

Regional Activities

■Ｐ01-02

In addition to its home market of Japan, Daiichi Sankyo’s

products are marketed in the United States and in many

countries in Europe and Asia. This global reach, and the

important insights it provides, is essential to our ability to

serve the diverse needs of patients and healthcare

professionals around the world. Through the creation and

supply of new drugs, Daiichi Sankyo’s contribution to

the health of people worldwide knows no borders, and to

foster this global perspective, we promote cross-company

information exchanges among such departments as

Research & Development, Supply Chain, and Marketing.

Global Business Activities

Our Business

Innovative pharmaceuticals continues to be the Group’s core

business area. We supply high-quality pharmaceuticals

that meet unmet medical needs, as well as the timely,

accurate, and easy-to-understand information that patients

and their physicians deserve.

Business Activities in JapanInnovative pharmaceuticals

Besides the research and early development and marketing

of vaccines carried out on its own, Daiichi Sankyo also

maintains strategic ties with two joint ventures: Kitasato

Daiichi Sankyo Vaccine Co., Ltd. (a joint venture with Kitasato

Institute), whose strength lies in production and chemistry,

manufacturing and controls (CMC), and Japan Vaccine Co.,

Ltd. ( a joint venture wi th GlaxoSmithK l ine ) , which

specializes in the latter phase of vaccine development and

sales. These alliances enable us to create a seamless

value chain, from discovery to the delivery of products,

ensuring a stable supply of the vaccines the public needs.

Vaccines

The concept of “self-medication” has become increasingly

common and customer needs have consequently become

increasingly diverse. It is with this background in mind that

the Daiichi Sankyo Group has established its consumer

healthcare business, which includes OTC pharmaceuticals,

functional skincare products, and food products, as one of

its core businesses. Daiichi Sankyo Healthcare Co., Ltd., a

Daiichi Sankyo Group company, is working to fur ther

develop the Group’s self-medication business.

OTC pharmaceuticals

Building on the trust and confidence that Daiichi Sankyo has

cultivated as a developer and manufacturer of innovative

drugs, Daiichi Sankyo Espha Co., Ltd. works to create the

added value that will allow it to supply quality generic

pharmaceuticals as well. Particularly in the area of product

safety, the Company manufactures products in dosage

forms and with labels designed for ease and accuracy of

use. These effor ts include, for example, inscribing the

name of the drug on both sides of tablets. Moreover,

Daiichi Sankyo has launched a series of premium generic

products that build upon the brand’s expertise and add

new value. We hope these products will help Daiichi Sankyo

reinforce its brand differentiation and capture a larger share

of the market.

Generic pharmaceuticals

Marketing

CSRHistory

Regional Activities

■Ｐ03-04

Latest information

Plexxikon Asubio Pharma

U3 Pharma

Scaffold-based drug discovery (SBDD) platform

Oncology

Small molecular medicines

Inflammation, regeneration

Neuropathy｠｠

Small molecular and peptide medicines

Original lead generation

Lead optimization

Daiichi Sankyo established the Global Executive Meeting of Research and Development (GEMRAD) as our top

decision-making body for global R&D. GEMRAD makes management-level “go/no-go” decisions on development

projects and manages global R&D activities across functions and regions. Its members represent various

divisions, including those responsible for R&D, global sales, licensing, pharmaceutical affairs and product

portfolios. This enables GEMRAD to make appropriate decisions based on comprehensive assessments covering

everything from research to marketing. Moreover, regular priority evaluation is also conducted for early-stage

development projects in progress, enabling effective resource investment based on portfolio strategy

Global Research Organization

Daiichi Sankyo

Daiichi Sankyo RD Novare

GEMRAD

Oncology, cardiovascular-metabolics and frontier areas

Small molecular medicines; antibody and biopharmaceuticals

Lead optimization

Translational research

Priority Areas・ Oncology　・ Cardiovascular-metabolism　・ Frontier Areas

・Oncology　・ Cardiovascular-metabolism　・ Pain

・ Thrombosis 　・ Hypertension 　・ Pain

Synthesis, analysis

Exploratory research

Biological evaluation, OMICS

Oncology

Antibody pharmaceuticals

Inflammatory and infectious diseases

Lead optimization

Aging process

Neurodegenerative disease

Venture ScienceLaboratories

Daiichi Sankyo Life Science Research Centre in India （RCI）

Tissue and Cell Research Center Munich （TCRM）

Daiichi Sankyo Global Research Organization

Priority areas at each R&D stage

Innovation born from diversity

Research Early-stage Development Late-stage Development Life Cycle Management

At the Daiichi Sankyo Group, research is carried out globally via a closely integrated network incorporating Japan, the

United States, Germany and India. In Japan, alongside the nucleus of Daiichi Sankyo, there is Daiichi Sankyo RD Novare,

which is responsible for technology platforms for drug development, and Asubio Pharma, which specializes in drug

development research.

Overseas, there is U3 Pharma, which specializes in researching antibodies for targeting cancer, Plexxikon, which utilizes

small molecule scaffold-based drug discovery, Daiichi Sankyo Life Science Research Centre in India (RCI), which focuses

on creating drugs for inflammatory and infectious diseases, and the Tissue and Cell Research Center Munich (TCRM),

which utilizes tissue research technology. Each company advances new drug research by utilizing its respective

strengths. In Japan, the Venture Science Research Laboratories carries out innovative drug development research to find

treatments for diseases with high unmet medical needs.

Latest information

At the Daiichi Sankyo Group, we implement research and development initiatives that precisely address unmet medical

needs so that we can contribute to improving the rate of satisfaction towards medical care in the future. The key

categories in the research and early-stage development phases are oncology and cardiovascular-metabolics, with

investment of resources concentrated accordingly.

Another area of focus is the frontier area, where we actively pursue new therapies and substances with novel

mechanisms of action, moving beyond the existing boundaries in the field of disease.

Marketing

CSRHistory

Regional Activities

■Ｐ05-06

Plexxikon Asubio Pharma

U3 Pharma

Scaffold-based drug discovery (SBDD) platform

Oncology

Inflammation, regeneration

Neuropathy｠｠

Small molecular and peptide medicines

Lead optimization

Daiichi Sankyo established the Global Executive Meeting of Research and Development (GEMRAD) as our top

decision-making body for global R&D. GEMRAD makes management-level “go/no-go” decisions on development

projects and manages global R&D activities across functions and regions. Its members represent various

divisions, including those responsible for R&D, global sales, licensing, pharmaceutical affairs and product

portfolios. This enables GEMRAD to make appropriate decisions based on comprehensive assessments covering

everything from research to marketing. Moreover, regular priority evaluation is also conducted for early-stage

development projects in progress, enabling effective resource investment based on portfolio strategy

Global Research Organization

Daiichi Sankyo

Daiichi Sankyo RD Novare

GEMRAD

Oncology, cardiovascular-metabolics and frontier areas

Small molecular medicines; antibody and biopharmaceuticals

Lead optimization

Priority Areas・ Oncology　・ Cardiovascular-metabolism　・ Frontier Areas

・Oncology　・ Cardiovascular-metabolism　・ Pain

・ Thrombosis 　・ Hypertension 　・ Pain

Synthesis, analysis

Exploratory research

Biological evaluation, OMICS

Oncology

Antibody pharmaceuticals

Inflammatory and infectious diseases

Lead optimization

Aging process

Neurodegenerative disease

Venture ScienceLaboratories

Daiichi Sankyo Life Science Research Centre in India （RCI）

Tissue and Cell Research Center Munich （TCRM）

Daiichi Sankyo Global Research Organization

Priority areas at each R&D stage

Innovation born from diversity

Research Early-stage Development Late-stage Development Life Cycle Management

At the Daiichi Sankyo Group, research is carried out globally via a closely integrated network incorporating Japan, the

United States, Germany and India. In Japan, alongside the nucleus of Daiichi Sankyo, there is Daiichi Sankyo RD Novare,

which is responsible for technology platforms for drug development, and Asubio Pharma, which specializes in drug

development research.

Overseas, there is U3 Pharma, which specializes in researching antibodies for targeting cancer, Plexxikon, which utilizes

small molecule scaffold-based drug discovery, Daiichi Sankyo Life Science Research Centre in India (RCI), which focuses

on creating drugs for inflammatory and infectious diseases, and the Tissue and Cell Research Center Munich (TCRM),

which utilizes tissue research technology. Each company advances new drug research by utilizing its respective

strengths. In Japan, the Venture Science Research Laboratories carries out innovative drug development research to find

treatments for diseases with high unmet medical needs.

Latest information

At the Daiichi Sankyo Group, we implement research and development initiatives that precisely address unmet medical

needs so that we can contribute to improving the rate of satisfaction towards medical care in the future. The key

categories in the research and early-stage development phases are oncology and cardiovascular-metabolics, with

investment of resources concentrated accordingly.

Another area of focus is the frontier area, where we actively pursue new therapies and substances with novel

mechanisms of action, moving beyond the existing boundaries in the field of disease.

Marketing

CSRHistory

Regional Activities

■Ｐ05-06

Our worldwide development network connects Japan, the United States, Europe, India and East Asian countries.

This multinational approach allows us to leverage expertise from around the world in executing clinical trials and

facilitating our global decision-making. Our Japanese bases, including Daiichi Sankyo RD Novare Co., Ltd., along with

Daiichi Sankyo Pharma Development, a U.S. development company based in the Edison, New Jersey, and the UK’s

Daiichi Sankyo Development Ltd. are working closely to advance the development of pharmaceuticals globally, while

managing and operating clinical testing in each respective region. In addition, as the Asian centers of our global

development, Daiichi Sankyo Korea, Daiichi Sankyo Taiwan, and Daiichi Sankyo （China） Holdings are contributing to the

ongoing launch of products.

A global development organization that connectsoperations in Japan and throughout the world

Global Development OrganizationJapan

Daiichi Sankyo Pharma Development

Daiichi Sankyo (Japan)

Daiichi Sankyo (China) Holdings Daiichi Sankyo Korea Daiichi Sankyo Taiwan Daiichi Sankyo

India Development

Daiichi Sankyo Development (U.K.)

Daiichi Sankyo Global Development Organization

United States

China South Korea Taiwan India

Europe

We recognize that we must earn the trust and confidence

of our customers every day, not only through the efficacy

and safety of our products, but also through the quality of

their manufacture as well. In order to assure the product

quality and responsibly maintain the market supply of safe

products, we have established a scientifically verified

process of production management that extends from the

import of raw materials to production and distribution.

Along that supply chain, we adhere to the most stringent

corporate and regu la tory s tandards, inc lud ing

internationally recognized standards set by Good

Manufacturing Practice （GMP）. We will continue to

implement global standard quality assurance to ensure

product safety and customer satisfaction.

Dedication to quality

Pharmaceutical companies have a mission to reliably and

consistently supply high-quality drugs. Daiichi Sankyo is

fulfilling this role by integrating its operations to consistently

procure raw materials and systematically manufacture

drugs, as well as by using its logistics function to rapidly and

reliably distribute products. This integration facilitates the

centralized management of information, enabling a flexible

and efficient manufacturing and supply system ( supply

chain management ).

Daiichi Sankyo has also established a stable supply system

for the global market by seamlessly linking its production

bases inside and outside of Japan. Consistently supplying

highly reliable products that reproduce the quality of the

drug as designed requires a production management

system relying on technical verification of both facility

and human operations. Through its quality and safety

management system, Daiichi Sankyo has established its

own high standards with world-class validation processes

and has developed a highly reliable global supply system.

Stable manufacturing and supply

Pharmaceuticals contribute to the health of people all

over the world, but no matter how good the product is,

there is no pharmaceutical that is completely free from

the risk of potential side effects. It is precisely for this

reason that Daiichi Sankyo has established internal

systems to ensure a high level of safety management. It

conducts ongoing training to make sure that each

employee is aware of and adheres to the Company's

safety policies. Daiichi Sankyo exhaustively compiles

safety management information （such as information on

side effects） from around the world and provides

accurate information on appropriate usage to medical

professionals. By implementing these efforts we promote

the proper use of pharmaceuticals, which will, in turn

reduce the risk of any potential harm to patients to a

bare minimum.

Safety management system

Securing high quality and safety; delivering a stable supply of world-class products

Daiichi Sankyo Daiichi Sankyo RD Novare

Marketing

CSRHistory

Regional Activities

■Ｐ07-08

Our worldwide development network connects Japan, the United States, Europe, India and East Asian countries.

This multinational approach allows us to leverage expertise from around the world in executing clinical trials and

facilitating our global decision-making. Our Japanese bases, including Daiichi Sankyo RD Novare Co., Ltd., along with

Daiichi Sankyo Pharma Development, a U.S. development company based in the Edison, New Jersey, and the UK’s

Daiichi Sankyo Development Ltd. are working closely to advance the development of pharmaceuticals globally, while

managing and operating clinical testing in each respective region. In addition, as the Asian centers of our global

development, Daiichi Sankyo Korea, Daiichi Sankyo Taiwan, and Daiichi Sankyo （China） Holdings are contributing to the

ongoing launch of products.

A global development organization that connectsoperations in Japan and throughout the world

Global Development OrganizationJapan

Daiichi Sankyo Pharma Development

Daiichi Sankyo (Japan)

Daiichi Sankyo (China) Holdings Daiichi Sankyo Korea Daiichi Sankyo Taiwan Daiichi Sankyo

India Development

Daiichi Sankyo Development (U.K.)

Daiichi Sankyo Global Development Organization

United States

China South Korea Taiwan India

Europe

We recognize that we must earn the trust and confidence

of our customers every day, not only through the efficacy

and safety of our products, but also through the quality of

their manufacture as well. In order to assure the product

quality and responsibly maintain the market supply of safe

products, we have established a scientifically verified

process of production management that extends from the

import of raw materials to production and distribution.

Along that supply chain, we adhere to the most stringent

corporate and regu la tory s tandards, inc lud ing

internationally recognized standards set by Good

Manufacturing Practice （GMP）. We will continue to

implement global standard quality assurance to ensure

product safety and customer satisfaction.

Dedication to quality

Pharmaceutical companies have a mission to reliably and

consistently supply high-quality drugs. Daiichi Sankyo is

fulfilling this role by integrating its operations to consistently

procure raw materials and systematically manufacture

drugs, as well as by using its logistics function to rapidly and

reliably distribute products. This integration facilitates the

centralized management of information, enabling a flexible

and efficient manufacturing and supply system ( supply

chain management ).

Daiichi Sankyo has also established a stable supply system

for the global market by seamlessly linking its production

bases inside and outside of Japan. Consistently supplying

highly reliable products that reproduce the quality of the

drug as designed requires a production management

system relying on technical verification of both facility

and human operations. Through its quality and safety

management system, Daiichi Sankyo has established its

own high standards with world-class validation processes

and has developed a highly reliable global supply system.

Stable manufacturing and supply

Pharmaceuticals contribute to the health of people all

over the world, but no matter how good the product is,

there is no pharmaceutical that is completely free from

the risk of potential side effects. It is precisely for this

reason that Daiichi Sankyo has established internal

systems to ensure a high level of safety management. It

conducts ongoing training to make sure that each

employee is aware of and adheres to the Company's

safety policies. Daiichi Sankyo exhaustively compiles

safety management information （such as information on

side effects） from around the world and provides

accurate information on appropriate usage to medical

professionals. By implementing these efforts we promote

the proper use of pharmaceuticals, which will, in turn

reduce the risk of any potential harm to patients to a

bare minimum.

Safety management system

Securing high quality and safety; delivering a stable supply of world-class products

Daiichi Sankyo Daiichi Sankyo RD Novare

Marketing

CSRHistory

Regional Activities

■Ｐ07-08

To grow in this rapidly changing business environment, Daiichi Sankyo reinforces strategy development

and effectiveness through a global management structure that includes three corporate units and four

functional units, as well as business units.

Our three corporate units – Corporate Strategy, Corporate Management, and General Affairs & Human Resources – support our CEO in developing comprehensive and consistent corporate strategies and ensuring smooth management of the Daiichi Sankyo Group.

Our business units include four corporate entities in the regions where we operate, as well as three business organizations: Sales & Marketing Unit, Vaccine Business Unit, and ASCA Company.

Our four functional units – R&D （Research & Development）, Pharmaceutical Technology, Supply Chain, and Quality & Safety – help formulate and execute global strategies. Each unit determines areas that should be expanded globally, guides strategic planning and execution, and improves the efficiency of business operations.

*ASCA: In-house term referring to markets outside Japan, the United States and Europe

Global Structure

Corporate Units

Business UnitsFunctional Units

Corporate Strategy Division

Sales & Marketing Unit ( Japan )

R&D Unit

Pharmaceutical Technology Unit

Supply Chain Unit

Quality & Safety Management Unit

Vaccine Business Unit ( Japan )

ASCA Company*

Secretariat Department

Internal Audit DepartmentCorporate Management Division

General Affairs &Human Resources Division

DSI Administrative and Commercial Operations ( U.S. )

Daiichi SankyoEurope GmbH ( Europe )

Luitpold Pharmaceuticals, Inc. ( U.S.)

Daiichi Sankyo Healthcare Co., Ltd. ( Japan)

Latest information

The antihypertensive agent olmesartan medoxomil is an

angiotensin II receptor blocker （ARB） which has a strong

and continuous antihypertensive action in comparison to

other drugs in its class and is expected to achieve superior

results in preventing end-organ damage. As a best-in-class

ARB, it was launched in the United States and Europe in

2002 and in Japan in 2004 (U.S. brand name, Benicar®;

Japanese and European brand name, Olmetec®). In recent

years, a large amount of data using Japanese subjects has

also been compiled. The praise garnered by this drug’s

strong antihypertensive action and high degree of

safety has been reflected in its sales around the world.

OlmesartanIn 2011, we launched edoxaban as Lixiana® in Japan. It

was the country’s first oral factor FXa inhibitor for the

prevention of venous thromboembolism (VTE ) in patients

undergoing orthopedic surgery in the lower limbs. In

addition, we have completed the ENGAGE AF-TIMI 48

study on the inhibition of the onset of cerebral apoplexy

( stroke) and systemic embol ism associated with

non-valvular atrial fibrillation ( irregular heart rate ), and the

HOKUSAI-VTE study for the treatment and prevention of

recurrences of venous thromboembolism (VTE ) in patients

with deep-vein thrombosis ( DVT ) or pulmonary embolism

(PE ). Sales began in Japan in December 2014 and in the

U.S. in February 2015. We look to obtain approval for sales

in Europe within 2015.

Edoxaban

Daiichi Sankyo discovered prasugrel with our Japanese

research partner, Ube Industries and developed it in

collaboration with Eli Lilly and Company. Prasugrel is an oral

antiplatelet agent that prevents blood clots. In 2009, we

launched it as Effient® in the United States and as Efient®

in Europe to prevent atherothrombotic events (causing

inflammation of the arteries) in patients with acute coronary

syndrome undergoing percutaneous coronary intervention

( PCI ). To date, prasugrel has been approved in more than

70 countries around the world. In Japan, we launched

Efient® for the treatment of patients with ischemic heart

disease undergoing PCI in May 2014, and are currently

conducting phase 3 studies on patients with ischemic

cerebrovascular disease.

Signature products created by original R&DTranslating years of knowledge and technology into outstanding products

Prasugrel

Latest information

Marketing

CSRHistory

Regional Activities

■Ｐ09-10

To grow in this rapidly changing business environment, Daiichi Sankyo reinforces strategy development

and effectiveness through a global management structure that includes three corporate units and four

functional units, as well as business units.

Our three corporate units – Corporate Strategy, Corporate Management, and General Affairs & Human Resources – support our CEO in developing comprehensive and consistent corporate strategies and ensuring smooth management of the Daiichi Sankyo Group.

Our business units include four corporate entities in the regions where we operate, as well as three business organizations: Sales & Marketing Unit, Vaccine Business Unit, and ASCA Company.

Our four functional units – R&D （Research & Development）, Pharmaceutical Technology, Supply Chain, and Quality & Safety – help formulate and execute global strategies. Each unit determines areas that should be expanded globally, guides strategic planning and execution, and improves the efficiency of business operations.

*ASCA: In-house term referring to markets outside Japan, the United States and Europe

Global Structure

Corporate Units

Business UnitsFunctional Units

Corporate Strategy Division

Sales & Marketing Unit ( Japan )

R&D Unit

Pharmaceutical Technology Unit

Supply Chain Unit

Quality & Safety Management Unit

Vaccine Business Unit ( Japan )

ASCA Company*

Secretariat Department

Internal Audit DepartmentCorporate Management Division

General Affairs &Human Resources Division

DSI Administrative and Commercial Operations ( U.S. )

Daiichi SankyoEurope GmbH ( Europe )

Luitpold Pharmaceuticals, Inc. ( U.S.)

Daiichi Sankyo Healthcare Co., Ltd. ( Japan)

Latest information

The antihypertensive agent olmesartan medoxomil is an

angiotensin II receptor blocker （ARB） which has a strong

and continuous antihypertensive action in comparison to

other drugs in its class and is expected to achieve superior

results in preventing end-organ damage. As a best-in-class

ARB, it was launched in the United States and Europe in

2002 and in Japan in 2004 (U.S. brand name, Benicar®;

Japanese and European brand name, Olmetec®). In recent

years, a large amount of data using Japanese subjects has

also been compiled. The praise garnered by this drug’s

strong antihypertensive action and high degree of

safety has been reflected in its sales around the world.

OlmesartanIn 2011, we launched edoxaban as Lixiana® in Japan. It

was the country’s first oral factor FXa inhibitor for the

prevention of venous thromboembolism (VTE ) in patients

undergoing orthopedic surgery in the lower limbs. In

addition, we have completed the ENGAGE AF-TIMI 48

study on the inhibition of the onset of cerebral apoplexy

( stroke) and systemic embol ism associated with

non-valvular atrial fibrillation ( irregular heart rate ), and the

HOKUSAI-VTE study for the treatment and prevention of

recurrences of venous thromboembolism (VTE ) in patients

with deep-vein thrombosis ( DVT ) or pulmonary embolism

(PE ). Sales began in Japan in December 2014 and in the

U.S. in February 2015. We look to obtain approval for sales

in Europe within 2015.

Edoxaban

Daiichi Sankyo discovered prasugrel with our Japanese

research partner, Ube Industries and developed it in

collaboration with Eli Lilly and Company. Prasugrel is an oral

antiplatelet agent that prevents blood clots. In 2009, we

launched it as Effient® in the United States and as Efient®

in Europe to prevent atherothrombotic events (causing

inflammation of the arteries) in patients with acute coronary

syndrome undergoing percutaneous coronary intervention

( PCI ). To date, prasugrel has been approved in more than

70 countries around the world. In Japan, we launched

Efient® for the treatment of patients with ischemic heart

disease undergoing PCI in May 2014, and are currently

conducting phase 3 studies on patients with ischemic

cerebrovascular disease.

Signature products created by original R&DTranslating years of knowledge and technology into outstanding products

Prasugrel

Latest information

Marketing

CSRHistory

Regional Activities

■Ｐ09-10

Increasing Synergy withJapanese Group CompaniesDaiichi Sankyo fuses the technological expertise of nine group companies within Japan that cover fields such as innovative pharmaceuticals, OTC pharmaceuticals, vaccines, and generic pharmaceuticals to create synergy throughout the entire value chain and deliver further value to its customers.

Daiichi Sankyo Espha Co., Ltd.

Generic Pharmaceuticals

Research and Development Business Support Services

OTC Pharmaceuticals

Vaccines

Based on the Dai ichi Sank yo Group’s corporate

ph i losophy o f “supp ly ing pharmaceut ica ls tha t

meet diverse medical needs,” Daiichi Sankyo Espha

operates business focusing on generic pharmaceuticals,

for which there is increased demand.

The company strives to deliver products that customers

can feel safe in using, not only in terms of quality,

information, and stable supply—the areas that are most

important to pharmaceutical customers—but also in

terms of af fordabi l i t y, which is expanded through

the availability of generic qua l i t y pharmaceuticals.

www.daiichisankyo-ep.co.jp

Daiichi Sankyo Healthcare Co., Ltd.Dai ichi Sankyo Healthcare is in charge of Dai ichi

Sankyo’s OTC pharmaceutical business, addressing

d ivers i fy ing needs accompanying the growth of

self-medication. Capitalizing on the R&D strengths at

the foundat ions of Dai ichi Sankyo, as wel l as i ts

marketing strengths, the company manufactures and

markets Rx-to-OTC switch drugs and other OTC

pharmaceuticals, as well as functional skincare and

food products, toward realizing “ Total Healthcare,”

which covers the entire body from head to toe.

About OTC Pharmaceuticals

OTC stands for “Over the Counter.” Unlike pharmaceuticals

prescribed by doctors, OTC pharmaceuticals can be

bought directly at pharmacies and drug stores without a

prescription. This includes both general pharmaceuticals

and guidance-required pharmaceuticals.

As the major global manufacturing base for pharmaceutical

products developed by Daiichi Sankyo, Daiichi Sankyo

Propharma strives to maintain a stable supply of high-

quality pharmaceuticals. The company also contributes to

the development of new products by manufacturing

investigational agents that are used in clinical trials.

www.daiichisankyo-pp.co.jp

Daiichi Sankyo Chemical Pharma is a pharmaceutical

manufacturer that supplies active pharmaceutical ingredients

and intermediates. Using its expertise in the factory

manufacturing process, the company efficiently achieves

fast development, stable supply, high quality and low cost,

and thus delivers its products faster, more cheaply and in a

more stable manner.

www.daiichisankyo-cp.co.jp

Manufacturing

Asubio Pharma is a drug discovery venture that creates and

disseminates innovative drug discovery concepts and

platforms to aid in the discovery of new drugs to meet

unmet medical needs. Asubio is developing business

specializing in drug discovery.

Daiichi Sankyo RD Novare Co., Ltd.

Daiichi Sankyo Propharma Co., Ltd.

Daiichi Sankyo Chemical Pharma Co., Ltd.

Daiichi Sankyo RD Novare is comprised of three units: a

drug discovery unit with an integrated initial drug discovery

function, an analysis center that provides a comprehensive

range of analytical services, and a clinical research

department that per forms high-quality clinical trial

monitoring and related tasks. The company thus plays a

critical role in the creation of innovative pharmaceuticals by

providing pharmaceutical R&D platforms.

www.daiichisankyo-rdn.co.jp

Daiichi Sankyo Business Associe Co., Ltd.Daiichi Sankyo Business Associe provides core general

business support services ( HR, accounting, sales-related

clerical tasks, purchasing, and general affairs ) for Daiichi

Sankyo Group companies on a subcontract basis. The

company also serves as an insurance and real estate

agency. Through its superior expertise in the pursuit of

both operational quality and efficiency, the company

ensures a h igh degree of customer satisfaction.

Daiichi Sankyo Happiness Co., Ltd.Daiichi Sankyo Happiness is a special company established

in accordance with the Employment Promotion Act for

Persons with Disabilities in order to promote the hiring of

disabled persons by the Daiichi Sankyo Group. The

company provides a variety of services to the group, such

as clothes cleaning, laboratory equipment cleaning and mail

services within the Group.

Launched as a joint venture between Daiichi Sankyo and

the Kitasato Institute, Kitasato Daiichi Sankyo Vaccine is a

core company that handles R&D and manufacturing for the

vaccine business. Working closely with the Kitasato Institute

and other research organizations and universities in Japan

and worldwide, the company per forms research and

development of new vaccines and manufactures and

markets high-quality, easy-to-administer vaccines.

www.daiichisankyo-kv.co.jp

Latest information

Kitasato Daiichi Sankyo Vaccine Co., Ltd.

Asubio Pharma Co., Ltd.

Increasing Synergy withJapanese Group CompaniesDaiichi Sankyo fuses the technological expertise of nine group companies within Japan that cover fields such as innovative pharmaceuticals, OTC pharmaceuticals, vaccines, and generic pharmaceuticals to create synergy throughout the entire value chain and deliver further value to its customers.

Daiichi Sankyo Espha Co., Ltd.

Generic Pharmaceuticals

Research and Development Business Support Services

OTC Pharmaceuticals

Vaccines

Based on the Dai ichi Sank yo Group’s corporate

ph i losophy o f “supp ly ing pharmaceut ica ls tha t

meet diverse medical needs,” Daiichi Sankyo Espha

operates business focusing on generic pharmaceuticals,

for which there is increased demand.

The company strives to deliver products that customers

can feel safe in using, not only in terms of quality,

information, and stable supply—the areas that are most

important to pharmaceutical customers—but also in

terms of af fordabi l i t y, which is expanded through

the availability of generic qua l i t y pharmaceuticals.

www.daiichisankyo-ep.co.jp

Daiichi Sankyo Healthcare Co., Ltd.Dai ichi Sankyo Healthcare is in charge of Dai ichi

Sankyo’s OTC pharmaceutical business, addressing

d ivers i fy ing needs accompanying the growth of

self-medication. Capitalizing on the R&D strengths at

the foundat ions of Dai ichi Sankyo, as wel l as i ts

marketing strengths, the company manufactures and

markets Rx-to-OTC switch drugs and other OTC

pharmaceuticals, as well as functional skincare and

food products, toward realizing “ Total Healthcare,”

which covers the entire body from head to toe.

About OTC Pharmaceuticals

OTC stands for “Over the Counter.” Unlike pharmaceuticals

prescribed by doctors, OTC pharmaceuticals can be

bought directly at pharmacies and drug stores without a

prescription. This includes both general pharmaceuticals

and guidance-required pharmaceuticals.

As the major global manufacturing base for pharmaceutical

products developed by Daiichi Sankyo, Daiichi Sankyo

Propharma strives to maintain a stable supply of high-

quality pharmaceuticals. The company also contributes to

the development of new products by manufacturing

investigational agents that are used in clinical trials.

www.daiichisankyo-pp.co.jp

Daiichi Sankyo Chemical Pharma is a pharmaceutical

manufacturer that supplies active pharmaceutical ingredients

and intermediates. Using its expertise in the factory

manufacturing process, the company efficiently achieves

fast development, stable supply, high quality and low cost,

and thus delivers its products faster, more cheaply and in a

more stable manner.

www.daiichisankyo-cp.co.jp

Manufacturing

Asubio Pharma is a drug discovery venture that creates and

disseminates innovative drug discovery concepts and

platforms to aid in the discovery of new drugs to meet

unmet medical needs. Asubio is developing business

specializing in drug discovery.

Daiichi Sankyo RD Novare Co., Ltd.

Daiichi Sankyo Propharma Co., Ltd.

Daiichi Sankyo Chemical Pharma Co., Ltd.

Daiichi Sankyo RD Novare is comprised of three units: a

drug discovery unit with an integrated initial drug discovery

function, an analysis center that provides a comprehensive

range of analytical services, and a clinical research

department that per forms high-quality clinical trial

monitoring and related tasks. The company thus plays a

critical role in the creation of innovative pharmaceuticals by

providing pharmaceutical R&D platforms.

www.daiichisankyo-rdn.co.jp

Daiichi Sankyo Business Associe Co., Ltd.Daiichi Sankyo Business Associe provides core general

business support services ( HR, accounting, sales-related

clerical tasks, purchasing, and general affairs ) for Daiichi

Sankyo Group companies on a subcontract basis. The

company also serves as an insurance and real estate

agency. Through its superior expertise in the pursuit of

both operational quality and efficiency, the company

ensures a h igh degree of customer satisfaction.

Daiichi Sankyo Happiness Co., Ltd.Daiichi Sankyo Happiness is a special company established

in accordance with the Employment Promotion Act for

Persons with Disabilities in order to promote the hiring of

disabled persons by the Daiichi Sankyo Group. The

company provides a variety of services to the group, such

as clothes cleaning, laboratory equipment cleaning and mail

services within the Group.

Launched as a joint venture between Daiichi Sankyo and

the Kitasato Institute, Kitasato Daiichi Sankyo Vaccine is a

core company that handles R&D and manufacturing for the

vaccine business. Working closely with the Kitasato Institute

and other research organizations and universities in Japan

and worldwide, the company per forms research and

development of new vaccines and manufactures and

markets high-quality, easy-to-administer vaccines.

www.daiichisankyo-kv.co.jp

Latest information

Kitasato Daiichi Sankyo Vaccine Co., Ltd.

Asubio Pharma Co., Ltd.

Daiichi Sankyo knows it must earn the trust of those who

use our products and services, as well as the governments,

NGOs and organizations with which we partner on our

social responsibility activities. To do so, we adhere to the

highest standards of corporate behavior, so that all of our

business operations comply with global norms and

standards. We also distribute comprehensive information

about our corporate activities, communicating honestly

with stakeholders in order to earn and maintain their trust.

A Company Worthy of Stakeholder Trust

Access to healthcare and medicine are important social

issues around the world. The Daiichi Sankyo Group strives

to offer a variety of solutions globally to advance society’s

access to quality healthcare.

It is estimated that more than one billion poor people

throughout the world suffer from AIDS, malaria, tuberculosis

and neglected tropical diseases. Additionally, there are

many others suffering from “orphan” diseases, where the

relatively small number of patients and high costs of R&D

result in limited medical progress despite the high need for

treatment for these intractable diseases.

We are engaging the talent and resources of the Daiichi

Sankyo Group in order to respond to unmet medical needs

throughout the world. This not only includes a focus on

treatments for wide-spread illness, but those considered to

be “orphan” diseases, as well.

In developing countries, access to medical services is

limited by economic and social conditions and poor

physical infrastructure, among other reasons. As a member

of the health and medical industry, the Daiichi Sankyo

Group contributes to solving these social issues in

cooperation with NGOs, national governments, and

local communities.

With the increasing globalization of business, the

international influence of corporate activities on the

environment and society is growing. Daiichi Sankyo strives

to contribute to the development of a sustainable society.

We conduct our corporate activities in accord with the laws

and regulations in each region while respecting international

norms and protecting the environments in which we operate.

Social Responsibility at the Daiichi Sankyo Group

The Daiichi Sankyo Group integrates corporate social responsibility into its business activities as part of its mission to contribute to the enrichment of quality of life around the world.

Corporate Social Responsibility

In emerging nations, access to medical services is hindered

due to undeveloped public healthcare insurance systems

and healthcare infrastructures, shortages of personnel in the

manufacture and quality control of pharmaceuticals, and

poverty. To make contributions in areas of India, Cameroon,

and Tanzania, where there are doctor shortages, poor

access to hospitals, or otherwise undeveloped healthcare

infrastructure, the Daiichi Sankyo Group, with repeated,

ample consultation with NGOs, has been working with

local governments and regional companies to provide

mobile medical services.

These activities have the goal of contributing to the UN

Millennium Development Goals (MDGs) to “Reduce Child

Mortality” and “Improve Maternal Health.” In these regions,

under a five-year plan starting in 2011, the Group is carrying

out work that includes vaccinations and health checkups for

expectant and nursing mothers.

In 2013, our mobile medical service provided care to

approximately 240,000 people in India, Cameroon, and

Tanzania. In addition, we not only provide health checkups

for expectant and nursing mothers and vaccinations for

infants, but we have also been carrying out a variety of

activities aimed at improving awareness of hygiene and

sustaining enthusiasm for childrearing among mothers,

including holding healthy baby contests that give awards to

healthy children. Going forward, we seek to further enrich

our activities in order to reduce infant death rates, improve

the health of expectant and nursing mothers, and prevent

the spread of HIV/AIDS, malaria, and other diseases.

Mobile Healthcare Field Clinics

Social Contribution Activities to Improve Medical Access

Contributions to Reducing Child Mortality and Improving Maternal Health

■See a video of our activities in Africa herewww.dai ichisankyo.co. jp/corporate/csr/contr ibut ion/medicalaccess/b3d2.html

Latest information

Marketing

CSRHistory

Regional Activities

■Ｐ13-14

Daiichi Sankyo knows it must earn the trust of those who

use our products and services, as well as the governments,

NGOs and organizations with which we partner on our

social responsibility activities. To do so, we adhere to the

highest standards of corporate behavior, so that all of our

business operations comply with global norms and

standards. We also distribute comprehensive information

about our corporate activities, communicating honestly

with stakeholders in order to earn and maintain their trust.

A Company Worthy of Stakeholder Trust

Access to healthcare and medicine are important social

issues around the world. The Daiichi Sankyo Group strives

to offer a variety of solutions globally to advance society’s

access to quality healthcare.

It is estimated that more than one billion poor people

throughout the world suffer from AIDS, malaria, tuberculosis

and neglected tropical diseases. Additionally, there are

many others suffering from “orphan” diseases, where the

relatively small number of patients and high costs of R&D

result in limited medical progress despite the high need for

treatment for these intractable diseases.

We are engaging the talent and resources of the Daiichi

Sankyo Group in order to respond to unmet medical needs

throughout the world. This not only includes a focus on

treatments for wide-spread illness, but those considered to

be “orphan” diseases, as well.

In developing countries, access to medical services is

limited by economic and social conditions and poor

physical infrastructure, among other reasons. As a member

of the health and medical industry, the Daiichi Sankyo

Group contributes to solving these social issues in

cooperation with NGOs, national governments, and

local communities.

With the increasing globalization of business, the

international influence of corporate activities on the

environment and society is growing. Daiichi Sankyo strives

to contribute to the development of a sustainable society.

We conduct our corporate activities in accord with the laws

and regulations in each region while respecting international

norms and protecting the environments in which we operate.

Social Responsibility at the Daiichi Sankyo Group

The Daiichi Sankyo Group integrates corporate social responsibility into its business activities as part of its mission to contribute to the enrichment of quality of life around the world.

Corporate Social Responsibility

In emerging nations, access to medical services is hindered

due to undeveloped public healthcare insurance systems

and healthcare infrastructures, shortages of personnel in the

manufacture and quality control of pharmaceuticals, and

poverty. To make contributions in areas of India, Cameroon,

and Tanzania, where there are doctor shortages, poor

access to hospitals, or otherwise undeveloped healthcare

infrastructure, the Daiichi Sankyo Group, with repeated,

ample consultation with NGOs, has been working with

local governments and regional companies to provide

mobile medical services.

These activities have the goal of contributing to the UN

Millennium Development Goals (MDGs) to “Reduce Child

Mortality” and “Improve Maternal Health.” In these regions,

under a five-year plan starting in 2011, the Group is carrying

out work that includes vaccinations and health checkups for

expectant and nursing mothers.

In 2013, our mobile medical service provided care to

approximately 240,000 people in India, Cameroon, and

Tanzania. In addition, we not only provide health checkups

for expectant and nursing mothers and vaccinations for

infants, but we have also been carrying out a variety of

activities aimed at improving awareness of hygiene and

sustaining enthusiasm for childrearing among mothers,

including holding healthy baby contests that give awards to

healthy children. Going forward, we seek to further enrich

our activities in order to reduce infant death rates, improve

the health of expectant and nursing mothers, and prevent

the spread of HIV/AIDS, malaria, and other diseases.

Mobile Healthcare Field Clinics

Social Contribution Activities to Improve Medical Access

Contributions to Reducing Child Mortality and Improving Maternal Health

■See a video of our activities in Africa herewww.dai ichisankyo.co. jp/corporate/csr/contr ibut ion/medicalaccess/b3d2.html

Latest information

Marketing

CSRHistory

Regional Activities

■Ｐ13-14

Established in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, Daiichi Sankyo has a rich history spanning more than 100 years. Below, we introduce our milestones, including those of Sankyo and Daiichi Pharmaceutical since the beginning.

2005Established by joint holding company of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.

2006Began operations of Daiichi Sankyo Healthcare Co.,Ltd.; Daiichi Sankyo, Inc.; and Daiichi Sankyo Europe GmbH

2007Began operations on April 1, 2007as the newDaiichi Sankyo Group

2008Acquired U3 Pharma AG of Germany and became a majority stakeholder in Ranbaxy Laboratories Limited of India

2009Launched Prasugrel, an antiplatelet agent and global product, in Germany (as Efient ®) and the United States (as Effient®)

History of Daiichi Sankyo Co., Ltd.

History of Sankyo Co., Ltd.1899Founded as Sankyo Shoten through a joint investment by businessmen Matasaku Shiobara, Shotaro Nishimura

and Genjiro Fukui 1910Dr. Umetaro Suzuki, a future Sankyo scientific adviser, made the world's first discovery of vitamin B11 ( Oryzanin®) in rice bran and established a foundation for the theory of vitamins

1913Changed company name from Sankyo Shoten to Sankyo Co., Ltd. Appointed Dr. Jokichi Takamine as first president

1949Listed on Tokyo Stock Exchange

1951Launched LULU® cold medicine

1977Launched Krestin®, an anticancer drug

1986Launched the anti-inflammatory, analgesic drug, Loxonin® in Japan

1989Globally launched Mevalotin®, a groundbreaking HMG-CoA reductase inhibitor ( hyperlipidemic drug )

1992Awarded the Ohkochi Memorial Grand Production Prize for Mevalotin®

1994Completed construction of head office building in Nihonbashi, Tokyo, Japan

1998Became the first pharmaceutical company in Japan to receive ISO 14001 environmental certification for its Onahama and Odawara plants

2010Launched Rezaltas®, a high-affinity ARB/ long-acting calcium antagonist compound, and Inavir ®, an anti-influenza virus agent

Began operations of Daiichi Sankyo Espha Co., Ltd.

2011Acquired Plexxikon Inc. of the United States

Began operations of KitasatoDaiichi Sankyo Vaccine Co., Ltd.

Launched Memary® for treatmentof Alzheimer's disease, Lixiana®, an oral FXa inhibitor, and Nexium®, a proton pump inhibitor

Consolidated Daiichi Sankyo headoffice and the head offices of JapanGroup companies in the Nihonbashiarea of Tokyo, Japan

2012Opened Daiichi Sankyo Kusuri Museum in Tokyo

Launched RANMARK®, an antibody that targets RANK ligand, and TENELIA ®, a therapeutic agent for type 2 diabetes

Began operations of Japan Vaccine Co., Ltd., a joint venture with GlaxoSmithKline K.K.

2013Launched Pralia®, a treatment for osteoporosis

2014Launched anti-platelet agent Effient® in Japan

History of Daiichi Pharmaceutical Co., Ltd.1915Founded as Arsemin Shokai by Dr. Katsuzaemon Keimatsu and five others

1965Completed construction of former head office building inNihonbashi, Tokyo, Japan

Launched the anti-fibrinolytic Transamin®

1966Launched Patex®, the first flexible medicated bandage

1993Launched Cravit®, a broad-spectrum oral antibacterial agent

1973Launched Karoyan®, a hair restoration agent

1985Launched Tarivid® a broad-spectrum oral antibacterial agent, in Japan and the former West Germany

1918Changed company name from Arsemin Shokai to Daiichi Pharmaceutical Co., Ltd.

Appointed Seinosuke Shibata as first president

1937Launched Therapol®, the first sulfa drug produced in Japan

Latest information

Marketing

CSRHistory

Regional Activities

■Ｐ15-16

Established in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, Daiichi Sankyo has a rich history spanning more than 100 years. Below, we introduce our milestones, including those of Sankyo and Daiichi Pharmaceutical since the beginning.

2005Established by joint holding company of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.

2006Began operations of Daiichi Sankyo Healthcare Co.,Ltd.; Daiichi Sankyo, Inc.; and Daiichi Sankyo Europe GmbH

2007Began operations on April 1, 2007as the newDaiichi Sankyo Group

2008Acquired U3 Pharma AG of Germany and became a majority stakeholder in Ranbaxy Laboratories Limited of India

2009Launched Prasugrel, an antiplatelet agent and global product, in Germany (as Efient ®) and the United States (as Effient®)

History of Daiichi Sankyo Co., Ltd.

History of Sankyo Co., Ltd.1899Founded as Sankyo Shoten through a joint investment by businessmen Matasaku Shiobara, Shotaro Nishimura

and Genjiro Fukui 1910Dr. Umetaro Suzuki, a future Sankyo scientific adviser, made the world's first discovery of vitamin B11 ( Oryzanin®) in rice bran and established a foundation for the theory of vitamins

1913Changed company name from Sankyo Shoten to Sankyo Co., Ltd. Appointed Dr. Jokichi Takamine as first president

1951Launched LULU® cold medicine

1977Launched Krestin®, an anticancer drug

1986Launched the anti-inflammatory, analgesic drug, Loxonin® in Japan

1989Globally launched Mevalotin®, a groundbreaking HMG-CoA reductase inhibitor ( hyperlipidemic drug )

1992Awarded the Ohkochi Memorial Grand Production Prize for Mevalotin®

1994Completed construction of head office building in Nihonbashi, Tokyo, Japan

1998Became the first pharmaceutical company in Japan to receive ISO 14001 environmental certification for its Onahama and Odawara plants

2010Launched Rezaltas®, a high-affinity ARB/ long-acting calcium antagonist compound, and Inavir ®, an anti-influenza virus agent

Began operations of Daiichi Sankyo Espha Co., Ltd.

2011Acquired Plexxikon Inc. of the United States

Began operations of KitasatoDaiichi Sankyo Vaccine Co., Ltd.

Launched Memary® for treatmentof Alzheimer's disease, Lixiana®, an oral FXa inhibitor, and Nexium®, a proton pump inhibitor

Consolidated Daiichi Sankyo headoffice and the head offices of JapanGroup companies in the Nihonbashiarea of Tokyo, Japan

2012Opened Daiichi Sankyo Kusuri Museum in Tokyo

Launched RANMARK®, an antibody that targets RANK ligand, and TENELIA ®, a therapeutic agent for type 2 diabetes

Began operations of Japan Vaccine Co., Ltd., a joint venture with GlaxoSmithKline K.K.

2013Launched Pralia®, a treatment for osteoporosis

2014Launched anti-platelet agent Effient® in Japan

History of Daiichi Pharmaceutical Co., Ltd.1915Founded as Arsemin Shokai by Dr. Katsuzaemon Keimatsu and five others

1965Completed construction of former head office building inNihonbashi, Tokyo, Japan

Launched the anti-fibrinolytic Transamin®

1966Launched Patex®, the first flexible medicated bandage

1993Launched Cravit®, a broad-spectrum oral antibacterial agent

1973Launched Karoyan®, a hair restoration agent

1985Launched Tarivid® a broad-spectrum oral antibacterial agent, in Japan and the former West Germany

1918Changed company name from Arsemin Shokai to Daiichi Pharmaceutical Co., Ltd.

Appointed Seinosuke Shibata as first president

1937Launched Therapol®, the first sulfa drug produced in Japan

Latest information

Marketing

CSRHistory

Regional Activities

■Ｐ15-16

■Ｐ17-18

Facts & Figures

( billion of yen )

FY2014 FY2015FY2011 FY2012 FY2013

1Q 2Q 3Q 4Q

Net sales . Revenue

YTD FY20131Q 252.52Q 516.43Q 807.14Q

Sales by segment (FY2013)

JapanNorth America

Net Sales of 1H, FY 2015 2Q

EuropeOther regions

Net sales of 1H,FY 2015 2Q478.8 billion（100％）

( billion of yen )

FY2013

Daiichi Sankyo Group: JapanDaiichi Sankyo Group: Europe

Daiichi Sankyo Group: North AmericaDaiichi Sankyo Group: Other regions

Ranbaxy Group

Sales share by segment

FY2014

( billion of yen )

Domestic sales Overseas sales Percent of sales

Overseas sales, percent of sales

Overseas salesDomestic salesPercent of sales

R&D expensesR&D ratio

( billion of yen )

R&D expenses

R&D expenses, percent of sales

R&D ratio

Financial Highlights ( as of April 2016)

＊From FY2013, International Financial Reporting Standards ( IFRS) is applied.

1Q 2Q 3Q 4Q

1Q2Q3Q4Q

JapanNorth America

Daiichi Sankyo Group

EuropeOther regions

Ranbaxy Group

1,118.2

FY2014213.7429.6694.4919.4

FY2015238.4478.8758.6

FY2014

FY2014FY2010 FY2011 FY2012 FY2013

( billion of yen )

Operating income . Operating profit

265.9139.9

37.036.0 191.2

FY2013 FY2014FY2010 FY2011 FY2012

1Q 2Q 3Q 4Q

( billion of yen )

Net income . Profit attributable to owners of the Company

YTD1Q2Q3Q4Q

FY2014 FY2015FY2011 FY2012 FY2013

FY2011 FY2012231.7 242.6456.0 484.2696.4 745.6938.7 997.9

FY2010 FY2011 FY2012 FY2013

FY2010 FY2011 FY2012194.3 185.120% 20%

183.018%

563.8554.5

392.5526.8

482.3 489.7469.8 477.7

51% 51%

486.7511.2

FY2014FY2011 FY2012 FY2013 FY2015

FY201320.855.7

100.174.4

FY201432.859.7

FY201549.197.0

150.4100.5

FY2011 FY201243.5 32.562.2 57.191.9 93.598.2

Otherregions

FY2013

554.5211.3

79.052.9

FY2014

549.2229.9

78.861.5

FY2013190.721%

FY2014

FY201311.030.874.960.9

FY201421.636.168.946.5

FY201534.970.7

FY2011 FY201225.3 20.437.0 24.417.5 51.510.4 66.6

Latest information

1,000 150

JapanNorthAmerica

Europe

Latest information

www.daiichisankyo.com

Corporate Brochure

■H04-01

Corporate Brochure - Daiichi Sankyo...Corporate Brochure H04-01 Corporate Philosophy Joji Nakayama...

Documents

Transcript of Corporate Brochure - Daiichi Sankyo...Corporate Brochure H04-01 Corporate Philosophy Joji Nakayama...